Investigational drug · Phase 2
EDG-7500
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertrophic Cardiomyopathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "EDG-7500"
First trial start
2024
Apr 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EDG-7500", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertrophic Cardiomyopathy
Approved drugs for the same conditions: Hypertrophic cardiomyopathy · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "EDG-7500" as an intervention, largest first.
Edgewise Therapeutics, Inc.Industry
NCT06011317 · 84 participants · Start Aug 14, 2023 · Primary completion May 23, 2024
Drug: EDG-7500; Placebo · For: Healthy Subjects
Sites: Tempe, Arizona; Lincoln, Nebraska
- A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)Active, not recruiting
Edgewise Therapeutics, Inc.Industry
NCT06347159 · 79 participants (planned) · Start Apr 11, 2024 · Primary completion Dec 2027
Drug: EDG-7500; EDG-7500 · For: Hypertrophic Cardiomyopathy
Sites: San Francisco, California; Stanford, California; Atlanta, Georgia · 21 sites in all
Edgewise Therapeutics, Inc.Industry
NCT07034768 · 37 participants · Start Jul 22, 2025 · Primary completion Dec 22, 2025
Drug: EDG-7500 · For: Renal Impairments
Sites: Miami, Florida; Orlando, Florida
Edgewise Therapeutics, Inc.Industry
NCT07324616 · 25 participants · Start Jan 26, 2026 · Primary completion Apr 7, 2026
Drug: EDG-7500 · For: Hepatic Impairment (HI)
Sites: Miami, Florida; Orlando, Florida
Edgewise Therapeutics, Inc.Industry
NCT07456059 · 24 participants · Start Mar 10, 2026 · Primary completion Jun 1, 2026
Drug: EDG-7500 · For: Healthy Adult Participants
Sites: Glendale, California
- A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500Completed
Edgewise Therapeutics, Inc.Industry
NCT06738836 · 8 participants · Start Dec 3, 2024 · Primary completion Jan 17, 2025
Drug: [14C]-EDG-7500 · For: Healthy Volunteer
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review.
Patel S, Gandhi A, Pabani A, et al. · J Am Heart Assoc 2026
- Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator.
Emter CA, Henze M, DuVall M, et al. · JCI Insight 2026
- Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology.
Li-Wen Chu E, Seung Kim D, Masri A · Card Fail Rev 2025
Also in development for Hypertrophic Cardiomyopathy
- HRS-1893Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · Obstructive Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.